FeesSafety
Pluang+

M Loves Vintage advances eyewear division with manufacturing talks, designer search, and e-commerce plans

Company Fundamentals
23 Oct 2026
GlobeNewsWire
View Source
Bullish
M Loves Vintage advances eyewear division with manufacturing talks, designer search, and e-commerce plans

M Loves Vintage Holdings is progressing its M Loves Optical eyewear division by engaging with potential manufacturers and designers to develop a vintage-inspired collection. The company plans to launch the collection primarily through an e-commerce platform, supported by marketing and distribution strategies to expand retail and wholesale opportunities. These efforts build on its Moda Optics joint venture and aim to establish a scalable sales model. Next steps include finalizing manufacturing partnerships, design, product specs, and online sales channels, with updates expected as milestones are reached.

M Loves Vintage Holdings' eyewear development progress is shared here with Consumer Cyclical sector market data for context. For readers following Consumer Cyclical stocks, here is Pluang's market snapshot as of Oct 23, 2026 18:51 WIB: Out of 134 priced US stocks, 30 rose and 100 fell. Notable movers include ATER at USD 0.66 (+5.36%), XPEV at USD 9.42 (+3.86%), and NCLH at USD 14.97 (-3.67%).

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
44 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App